Entinostat + Lapatinib

The combination of entinostat and lapatinib is a therapeutic approach being investigated for HER2-positive breast cancer. This combination has shown promising results in preclinical and clinical studies. Entinostat is a class I histone deacetylase (HDAC) inhibitor that works by modifying gene expression through epigenetic mechanisms. Lapatinib is a dual tyrosine kinase inhibitor that targets both HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor). ## Mechanism and Efficacy The combination demonstrates synergistic anti-tumor effects both in vitro and in vivo. The mechanism involves: 1. Downregulation of phosphorylated Akt 2. Activation of FOXO3 transcriptional activity 3. Induction of Bim1 (a pro-apoptotic protein)[2] In preclinical models, the combination showed enhanced anti-tumor effects compared to either drug alone, with significant tumor shrinkage or growth inhibition in xenograft mouse models[2]. The combination was particularly effective in trastuzumab-resistant HER2-positive breast cancer cells[1]. ## Clinical Development A phase 1b dose escalation study was conducted to assess: - Maximum tolerated dose (MTD) - Safety and toxicity - Clinical efficacy - Pharmacodynamic biomarkers[1] The MTD was determined to be: - Lapatinib: 1000 mg daily - Entinostat: 12 mg every other week - When combined with trastuzumab: 8 mg/kg followed by 6 mg/kg every 3 weeks[1] ## Safety Profile Common adverse events included: - Diarrhea (89%) - Neutropenia (31%) - Thrombocytopenia (23%) - Hypokalaemia[1] Despite these side effects, the combination was deemed safe with acceptable tolerability[1][3]. ## Clinical Response Among 35 patients with evaluable response: - Partial response (PR) was observed in 3 patients - Complete response (CR) in 3 patients - Stable disease (SD) for over 6 months in 1 patient[1] The entinostat, lapatinib, and trastuzumab regimen showed effectiveness in patients who had progressed on trastuzumab treatment[3]. This combination represents a promising approach for treating HER2-positive metastatic breast cancer, particularly for patients who have developed resistance to standard HER2-targeted therapies.